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In November 2013, the United States Food and Drug Administration
set off a media ﬁrestorm (or what passes for one in our world) when it
sent a warning letter to the highest-proﬁle direct-to-consumer genetic
testing company, Silicon Valley-based 23andMe (Gutierrez, 2013). The
company, the agency alleged, had committed a litany of transgressions
during its six years in business, most notably violation of the Federal
Food, Drug and Cosmetic Act by marketing its spit kit and Personal
Genome Service (PGS) as a medical device without proper FDA clear-
ance. By doing so, the FDA averred, 23andMe had put its customers at
risk because they might “self-manage their treatments through dose
changes or even abandon certain therapies depending on the outcome”
of the company's PGS test. Or, in the case of hereditary breast and ovar-
ian cancer caused by mutations in the BRCA1 and BRCA2 genes, “if the
BRCA-related risk assessment for breast or ovarian cancer reports a
false positive, it could lead a patient to undergo prophylactic surgery,
chemoprevention, intensive screening, or other morbidity-inducing
actions, while a false negative could result in a failure to recognize an ac-
tual risk that may exist” (Gutierrez, 2013).
Setting aside all of the other complaints in the FDA's missive
(e.g., the company launching a high-proﬁle ad campaignwhile ignoring
the agency's communiqués for months on end), the implications were
clear: as far as the FDA was concerned, 23andMe could not be trusted
to dispense information on genetic risks for actionable traits with fairly
high penetrance like drug response and Mendelian forms of cancer.
This aspect of l'affaire 23andMe was a surprise: recent criticism of the
company's assessment of a single pharmacogenetic locus notwithstand-
ing (Brownstein et al., 2014), it seems to me that most—and arguably
themost robust—criticisms of the substance of DTC genetics companies'
offerings have been directed at their speculative and often contradictory
lifetime risk estimates for complex diseases derived from genome-wide
association studies (Peikoff, 2013; Ng et al., 2009; Janssens et al., 2011;
Kido et al., 2013; Kalf et al., 2014). Thus, for the FDA to attack the
company's assessment of the genetic basis of warfarin metabolism or
BRCA alleles seemed less convincing: would any self-respecting surgical
oncologist subject a woman to a radical mastectomy and/or oophorec-
tomy based on nothing more than a $99 direct-to-consumer test that
examined three known pathogenic alleles out of many hundreds
(Meric-Bernstamet al., 2013)? Thiswould be akin to anob-gyn forgoing
both a blood hCG pregnancy test and a pelvic exam because her patient
had already reported a positive home pregnancy test.http://dx.doi.org/10.1016/j.atg.2014.06.003
2212-0661/© 2014 Elsevier B.V. This is an open access article under the CC BY-NC-ND license2. The remainder of the proof is left as an exercise for the reader
Perhaps more surprising still was the FDA's insistence that it sup-
ports the development of a direct-to-consumer model (Hamburg,
2013) and does not wish to stand between Americans and their ge-
nomes. “People have every right to get their data,” the agency's Alberto
Gutierrez told Bloomberg Businessweek a few days after thewarning let-
ter to 23andMe he authored became public (Brady, 2013). And indeed,
even though 23andMe customers can no longer get access to the
company's interpretations of their health-related alleles while they
wait for 23andMe to satisfy the FDA's demands, they can still download
their rawgenotypedata from23andMe.comandupload those hundreds
of thousands of alleles to any number of freely available genome inter-
pretation sites (Cariaso and Lennon, 2012; Karczewski et al., 2012;
Angrist, 2014; Greshake et al., 2014). The message, then, seems to be
that the FDA is comfortable with the idea of American citizens having
access to their own uninterpreted (and, at the moment, mostly uninter-
pretable) genomic data and making of those data what they (and/or
others) will. The agency is not comfortable with people relying on a
company's interpretations about alleles related to health information
as extrapolated from the literature.
For its part, the company appears to have accepted this constraint
(and I suppose, other than moving the entirety of its operations off-
shore, what else could it do?). As ofmid-2014 itwas reportedlyworking
toward FDA compliance while remaining committed to the direct-to-
consumer model and recently reported FDA's agreement to review the
company's health report on genetic risk of Bloom Syndrome (Hibbs,
2014; Lee, 2014).
3. CSERs must render unto Caesar?
The kerfufﬂe surrounding 23andMe's tête-à-tête-gone-public with
the FDA can be (and has been) seen as a proxy for any number of com-
peting values: autonomy versus beneﬁcence (Vayena, 2014); free
speech versus consumer protection (Baudhuin, 2014); risk mitiga-
tion versus patient empowerment (Downing and Ross, 2014; Green
and Farahany, 2014); and perhaps investigational-use-only versus
research-use-only devices (Ray, 2013). I'm sure there are others. But
in each case the crux of the debate—is PGS subject to FDA oversight?—
has hinged upon 1) what 23andMe is (a commercial enterprise); and
2) what it is doing (marketing and selling parsed genetic information
to consumers without the involvement of medical professionals).(http://creativecommons.org/licenses/by-nc-nd/3.0/).
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The FDA, it seems, is interested not only in direct-to-consumer geno-
mics, but in “indirect-to-patient” genomics as well. The Clinical Se-
quencing Exploratory Research Program, an initiative funded by the
National Human Genome Research Institute and the National Cancer
Institute since 2011, is a network of research projects aimed at assessing
the impact of large-scale sequencing in a range of clinical settings
(https://cser-consortium.org/projects). In recent months three inde-
pendent sources from different CSER projects (none of which I am afﬁl-
iatedwith) have toldme that the FDA has had discussionswith them on
whether the CSERs might need Investigational Device Exemptions
(IDEs) and/or other regulatory submissions related to their clinical
sequencing research programs. While the agency approved a sequenc-
ing machine and associated reagents for clinical genomics in 2013
as well as particular assays related to cystic ﬁbrosis variant detection
(Anonymous, 2014), it has yet to publicly signal any broad regulatory
plans with respect to large-scale sequencing protocols in clinical set-
tings per se.
That said, the FDA has long since made it known that it believes that
regulation of so-called molecular-based laboratory-developed tests is
within its purview (Davis and Wentz, 2007), despite resistance from
the clinical pathology community (Scott et al., 2013; Ferreira-Gonzalez
et al., 2014). So maybe this is neither a surprise nor a big deal. Certainly
many legitimate questions remain about next-generation clinical se-
quencing, among them: how many mutations must one clinically vali-
date? What are acceptable false positive and false negative rates? And
what is the appropriate comparator technology (Pant et al., 2014)?
But those aremore about assays than they are about research partic-
ipation. As constituted, the CSERs are research studies already subject to
both institutional reviewboard and NIH/NCI oversight, neither of which
is trivial (ask any principal investigator doing human subjects research
or any IRB member). The CSERs carry out sequencing in clinically certi-
ﬁed laboratories regulated by the Centers for Medicare and Medicaid
Services; they are not in it tomakemoney nor are they returning results
to patients without physician involvement (not that there's anything a
priori wrong with either of those things). On the contrary: one might
argue that the raison d'etre of the CSERs is to explicitly involve physi-
cians and clinical genetics researchers in the non-commercial clinical
sequencing enterprise.
4. Department of redundancy department?
It is clear that 23andMe has work to do rebuilding its image and rec-
onciling its promises with its product, to say nothing of ﬁnding its way
into the good graces of the FDA. Each of those will take time. So be it.
But federally funded clinical sequencing experiments can hardly be
accused of “going rogue.” If the FDA is sincere in its wish to “promote in-
novation” in personalized medicine and thereby “improve the care and
treatment of patients” (http://www.fda.gov/newsevents/speeches/
ucm387755.htm), it ought to tread carefully in its overtures to regulat-
ingmedical genomics in its bold but iterative instantiations in the clinic.
To impose additional oversight on something that is already being over-
seen by academic medical institutions as well as individual clinicians
and researchersmight be simple prudence: no onewho's involved in al-
most any aspect of a clinical sequencing pipeline would argue that it is
not hard to build and execute well, whether in healthy people or in
patients. It is critical that we get this right.
But more regulation is not always better regulation. For those in-
volved in clinical sequencing at an academic medical center, satisfying
one's local IRB can feel like a full-time job. It would be a shame if onemore agency's good intentions ended up as an exercise in “piling on”
and fanning the ﬂames of genetic exceptionalism.
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